Celgene Corporation (CELG) Shares Bought by Janus Henderson Group PLC
Janus Henderson Group PLC raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 4,290.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,408,961 shares of the biopharmaceutical company’s stock after purchasing an additional 8,217,433 shares during the quarter. Celgene accounts for 0.7% of Janus Henderson Group PLC’s portfolio, making the stock its 15th largest position. Janus Henderson Group PLC owned approximately 1.07% of Celgene worth $1,092,071,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of CELG. BlackRock Inc. raised its holdings in shares of Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after acquiring an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares during the last quarter. State Street Corp raised its holdings in shares of Celgene by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Celgene by 1.2% during the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after acquiring an additional 156,864 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of Celgene by 5.9% during the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after acquiring an additional 697,250 shares during the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.
Celgene Corporation (CELG) opened at $102.73 on Friday. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17. The stock has a market capitalization of $80,880.00, a PE ratio of 16.02, a P/E/G ratio of 0.79 and a beta of 1.77.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the previous year, the company earned $1.58 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. analysts expect that Celgene Corporation will post 6.67 EPS for the current year.
In other news, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. 0.95% of the stock is currently owned by insiders.
CELG has been the subject of a number of analyst reports. Robert W. Baird restated a “buy” rating and issued a $162.00 price target on shares of Celgene in a research report on Thursday, September 21st. Jefferies Group reiterated a “buy” rating and issued a $160.00 price objective on shares of Celgene in a research report on Friday, September 15th. Mizuho increased their price objective on Celgene from $134.00 to $158.00 and gave the stock a “buy” rating in a research report on Friday, September 15th. Vetr lowered Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a research report on Tuesday, August 29th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Celgene in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $139.57.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.